**Core Concept**
Myasthenia gravis is an autoimmune disease characterized by weakness and fatigue of skeletal muscles, caused by antibodies targeting the acetylcholine receptor (AChR) at the neuromuscular junction (NMJ). The condition requires careful management to avoid exacerbating symptoms.

**Why the Correct Answer is Right**
Aminoglycoside antibiotics, such as A, can exacerbate myasthenia gravis by blocking acetylcholine release from nerve terminals, further impairing neuromuscular transmission. This is due to their mechanism of action, which involves binding to the bacterial 30S ribosomal subunit and inhibiting protein synthesis. In the context of myasthenia gravis, this can lead to increased muscle weakness and fatigue.

**Why Each Wrong Option is Incorrect**
**Option B:** Aminophylline, a phosphodiesterase inhibitor, is actually used in the treatment of myasthenia gravis to enhance neuromuscular transmission. It works by increasing the concentration of cyclic AMP (cAMP) in skeletal muscle cells, thereby increasing the release of acetylcholine.

**Option C:** Corticosteroids, such as prednisolone, are a mainstay of treatment for myasthenia gravis, as they reduce inflammation and suppress the autoimmune response. They are not contraindicated in myasthenia patients.

**Option D:** Cholinesterase inhibitors, such as pyridostigmine, are also used to treat myasthenia gravis by increasing the concentration of acetylcholine in the synaptic cleft, thereby enhancing neuromuscular transmission.

**Clinical Pearl / High-Yield Fact**
Aminoglycoside antibiotics can exacerbate myasthenia gravis by blocking acetylcholine release from nerve terminals, highlighting the importance of careful medication management in patients with this condition.

**Correct Answer: A. Aminoglycoside antibiotics can exacerbate myasthenia gravis by blocking acetylcholine release from nerve terminals.**